Deutscher Platz 5a
49 341 48792 40
Impiegati a tempo pieno: 775
|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Jakub Julian Baran||Chairman of the Management Board & CEO||N/D||N/D||N/D|
|Mr. Tomasz Franciszek Baran||VP of the Management Board & Chief Commercial Officer||N/D||N/D||N/D|
|Mr. Dirk Plaga||CFO & Member of Management Board||N/D||N/D||1965|
|Santiago Luengo||Managing Director of Secuvita||N/D||N/D||N/D|
VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous immune cells; and CAR-T. In addition, the company manufactures advanced therapy medicinal products based on mesenchymal stem cells for experimental treatment by specialized medical institutions; preserves stem cells from perinatal tissue and adult body fat; and engages in the contract manufacturing of pharmaceutical intermediates. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.
L'ISS Governance QualityScore di VITA 34 AG al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.